Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies by Kim, Mikyung et al.
Biochemical and Functional Analysis of Smallpox Growth Factor
(SPGF) and Anti-SPGF Monoclonal Antibodies*□S
Received for publication, January 13, 2004, and in revised form, March 9, 2004
Published, JBC Papers in Press, April 7, 2004, DOI 10.1074/jbc.M400343200
Mikyung Kim‡§, Hailin Yang‡§, Sung-Kwon Kim§¶, Pedro A. Reche‡§, Rebecca S. Tirabassi¶,
Rebecca E. Hussey‡, Yasmin Chishti‡, James G. Rheinwald, Tiara J. Morehead**, Tobias Zech‡,
Inger K. Damon**, Raymond M. Welsh¶, and Ellis L. Reinherz‡ ‡‡
From the ‡Laboratory of Immunobiology, Department of Medical Oncology, Dana-Farber Cancer Institute and Department
of Medicine, Harvard Medical School, Boston, Massachusetts 02115, ¶Department of Pathology, University of
Massachusetts Medical Center, Worcester, Massachusetts 01655, Department of Dermatology, Brigham and Women’s
Hospital, Harvard Medical School, Boston, Massachusetts 02115, and **Poxvirus Section, Centers for Disease Control and
Prevention, Atlanta, Georgia 30333
Variola, the causative agent of smallpox, is a highly
infectious double-stranded DNA virus of the orthopox
genus that replicates within the cytoplasm of infected
cells. For unknown reasons prominent skin manifesta-
tions, including “pox,” mark the course of this systemic
human disease. Here we characterized smallpox growth
factor (SPGF), a protein containing an epidermal
growth factor (EGF)-like domain that is conserved
among orthopox viral genomes, and investigated its pos-
sible mechanistic link. We show that after recombinant
expression, refolding, and purification, the EGF domain
of SPGF binds exclusively to the broadly expressed cel-
lular receptor, erb-B1 (EGF receptor), with subnanomo-
lar affinity, stimulating the growth of primary human
keratinocytes and fibroblasts. High affinity monoclonal
antibodies specific for SPGF reveal in vivo immunopro-
tection in a murine vaccinia pneumonia model by a
mechanism distinct from viral neutralization. These
findings suggest that blockade of pathogenic factor ac-
tions, in general, may be advantageous to the infected
host.
Before its eradication, smallpox was a devastating disease
afflicting humans for greater than 3000 years with signifi-
cant morbidity and mortality (1). Variola virus enters
through the respiratory tract, and human-human transmis-
sion usually occurs via large respiratory droplets. The asymp-
tomatic, non-infectious incubation period averages 10–12
days (range 7–19 days) followed by fever, headache, and
backache with a subsequent rash appearing on the face,
trunk, and extremities and progressing to vesicles, pustules,
and scabs lasting for several weeks. This rather lengthy
incubation period provides time for naive, unvaccinated in-
dividuals to receive protective immunotherapy.
Large scale immunization with vaccinia virus (VV)1 largely
eliminated smallpox in Europe and North America by 1940.
Subsequently, in 1967 the World Health Organization launched
an intensified worldwide vaccination campaign resulting in erad-
ication of smallpox by 1980 and cessation of vaccination (1).
Given the susceptibility of unvaccinated individuals, the per-
ceived potential for smallpox to be exploited as a mortality-
inducing bioweapon is significant. In addition, immunization
with VV is considered risky in immunocompromised or immuno-
suppressed individuals. However, advances in both immunology
and genomic analysis may offer new possibilities for eliciting
immune protection without the requirement for live-virus vacci-
nation and attendant complications (2).
Viruses have evolved mechanisms to evade detection and
destruction by the host immune system. One of the evasion
strategies that has been adopted by large DNA viruses such as
poxviruses and herpesviruses is to encode homologues of cyto-
kines and chemokines and their receptors involved in immune
modulation (3, 4). In the present report we employed genome-
wide bioinformatic analysis to identify potential immune-ac-
cessible targets from variola virus for purposes of immunopro-
tection. Functional annotation indicated that one candidate
protein, D4R, which is conserved among all Orthopoxvirus,
corresponds to the variola virus counterpart of the vaccina
growth factor precursor (5). Vaccinia growth factor (VGF) is an
early gene product involved in vaccinia pathogenesis. Host cell
proliferative responses to vaccinia virus are mediated by VGF,
and not surprisingly, deletion of the VGF factor gene reduces
virus virulence in vivo (6, 7). Structurally, VGF is a highly
glycosylated soluble factor related to the epidermal growth
factor (EGF) superfamily, whose signature feature is the pres-
ence of an EGF-like domain (5, 8). Signaling by EGF-like li-
gands is mediated via four cell surface erb-B receptor kinases.
Erb-B1, the epidermal growth factor receptor (EGFR), as well
as erb-B2, -B3, and -B4 and their ligands have been studied in
detail (for review, see Ref. 9). Poxviruses, including vaccinia,
exploit the erb-B signaling network via their EGF-like growth
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Thus, given the connection between viral pathogenesis and
the expression of these EGF-like growth factors, we have iso-
lated the smallpox growth factor (SPGF) from variola virus
encoded by the D4R gene and expressed and purified the rele-
vant recombinant fragment for functional studies, defining the
human cellular target of SPGF. Monoclonal antibodies against
this pathogenic factor were produced. Those with sufficiently
high affinity and cross-reactive with the structurally related
VGF were tested in a murine vaccine pneumonia in vivo model.
The results suggest that blockade of viral secreted factors pro-
moting pathogenesis may be advantageous for the infected host
in general.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—Recombinant protein frag-
ments of SPGF (D4R) and VGF (C11R) (residues 40–90) were con-
structed by PCR and subcloned into the pET15b vector using NdeI and
BamHI restriction sites. In the resulting plasmid protein was expressed
under the control of the T7 promoter as a fusion with a His6 tag followed
by a thrombin cleavage sequence at the N terminus. Protein was in-
duced in Escherichia coli with isopropyl-1-thio--D-galactopyranoside
at an A600 of about 0.6 and harvested after 3 h of induction. The
inclusion bodies were isolated and dissolved in 10 mM Tris, pH 8,
containing 6 M guanidine HCl and 10 mM 2-mercaptoethanol. After
oxidation overnight at room temperature, the protein was purified
using a Ni2-nitrilotriacetic acid-agarose column. The partially purified
protein was diluted to 100 g/ml with 4 M guanidine HCl and dialyzed
extensively at 4 °C against a 50 mM Tris, pH 9, buffer containing 50 mM
NaCl, 2 mM reduced glutathione, and 1 mM oxidized glutathione. After
three buffer exchanges over a 72-h period, during which oxidative
refolding occurs, the refolded protein was buffer-exchanged to 20 mM
sodium phosphate, pH 6.5, and 100 mM NaCl. Using a preparative C18
reverse-phase column, more than 90% of the refolded protein separated
as a single sharp peak. Electrospray analysis on a mass spectrometer
(Qstar Pulsar I) gave mass values of 7907 and 7870 Da for SPGF and
VGF, respectively, consistent with their theoretical masses.
Chemical Cross-linking of SPGF and erb-B Receptors—2.25  106
MB468 or MB453 cells were pretreated with 0.04% NaN3 at 4 °C for 30
min to inhibit receptor internalization. Then biotinylated SPGF at 1
g/ml was incubated with the cells for 30 min at 4 °C. The dishes were
washed with ice-cold Dulbecco’s modified Eagle’s medium. Bis(sulfos-
uccinimdyl) suberate (BS3) cross-linker was added to 1 mM and incu-
bated for an additional 1 h at 4 °C with occasional shaking. After 2
washes with ice-cold PBS, 1 ml of lysis buffer (25 mM Tris, pH 7.4, 150
mM NaCl, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 0.35
trypsin inhibitor units/ml aprotinin, and 5 g/ml leupeptin) was added
directly to the dishes followed by shaking at 4 °C for 30 min. Samples
were spun down, and the supernatants were subjected to immunopre-
cipitation with 1 g of anti-erb-B1, anti-erb-B3, or anti-erb-B4 (Santa
Cruz) goat polyclonal antibodies or a 1:40 dilution of anti-erb-B2 (Cell
Signaling) rabbit polyclonal antibody using 10 l of GammaBindTM plus
beads. After rotating at 4 °C for 5 h, the beads were washed 4 times
with 1  Tris-buffered saline, 1% Triton X-100 followed by boiling the
beads directly in 2 SDS loading buffer. SDS-PAGE and Western
blotting by streptavidin-HRPO were used to reveal the biotinylated
erb-B receptors.
For analysis of erb-B receptor subtype-specific expression in MB468
and MB453 cells, lysates as above were immunoprecipitated with the
anti-erbB antisera and then Western-blotted with the same antibodies
used for immunoprecipitation in the case of erb-B1 and erb-B3 and goat
anti-erb-B2 polyclonal antibody (Cell Signaling Technology Inc.) and
rabbit anti-erb-B4 polyclonal antibody (Santa Cruz) for erb-B2 and
erb-B4, respectively. All membrane treatments are as described subse-
quently for Western-blotting analysis under “Experimental Procedures”
except an anti-rabbit IgG HRPO conjugate was employed for erb-B4
detection.
Monoclonal Antibody Production and Enzyme-linked Immunosor-
bant Assay (ELISA) Screening—To generate monoclonal antibodies
(mAbs) using recombinant SPGF protein, 8-week-old BALB/c mice were
immunized (intraperitoneally) with 50 g of SPGF 4–5 times at 2-week
intervals. The first immunization was done in Freund’s complete adju-
vant followed by incomplete Freund’s adjuvant for subsequent immu-
nization. Mice were sacrificed 5 days after the final boost, and the cells
from splenocytes were fused with NS-1 myeloma cells using a standard
fusion protocol (11). Hybridomas were screened by ELISA. Antibody-
secreting hybridomas were cloned twice by limiting dilution before
being inoculated into pristane-primed mice for production of ascitic
fluid. mAbs were purified using a protein G column. The three mAbs
used in this study, 2-22, 11D7, and 13E8, are all of the IgG2b isotype.
ELISA was performed in 96-well plates to which Ni2-nitrilotriacetic
acid had been coated (Ni-NTA HisSorb, Qiagen). 50 l of SPGF at a
concentration of 5 g/ml in PBS containing 1% BSA and 0.05% Tween
20 were plated on nickel plates for 5 h at 4 °C followed by washing three
times with PBS containing 0.1% BSA and 0.05% Tween 20. 50 l of each
hybridoma supernatant were added per well and incubated overnight at
4 °C with shaking. After washing 3 times with PBS containing 0.1%
BSA and 0.05% Tween 20, 50 l of goat anti-mouse IgG (HL)-horse-
radish peroxidase conjugate (Bio-Rad) were added for 90 min (1:2000
dilution) in 1% BSA and PBS buffer at 4 °C. Plates were washed twice
with 0.1% BSA, 0.05% Tween 20 in PBS buffer and twice with PBS
alone and developed with ortho-phenylene diamine as a substrate. The
reaction was stopped after 7 min with 2.25 M H2SO4. The optical density
at 490 nm was measured.
Surface Plasmon Resonance Binding Analyses—All experiments
were performed on a BIAcore 3000 instrument (Biacore, Piscataway,
NJ) at 25 °C in Hepes-buffered saline running buffer (150 mM NaCl, 3.4
mM EDTA, 0.005% surfactant P-20, 10 mM Hepes, pH 7.4). To test the
antigenic reactivity of 2-22, 11D7, and 13E8 antibody to SPGF and
VGF, each antibody was coupled to the CM5 chip surface using an
amine coupling kit at a flow rate of 5 l/min. Then SPGF and VGF at a
concentration of 8 g/ml were individually passed over each immobi-
lized antibody surface. The sensor surface was regenerated between
binding reactions by 2 washes of 10 mM glycine buffer, pH 9.5, for 15 s
at 100 l/min. For determination of the kinetics of antigen-antibody
binding, 2-22 and 13E8 mAbs were individually immobilized on the
CM5 chip surface using a standard amine coupling procedure. For each
antibody, all experiments were performed on three surfaces of different
ligand densities ranging from 1000 to 1500 response units. Association
was measured by passing various concentrations of SPGF or VGF (1–10
nM) over each ligand surface for 2 min at a flow rate of 50–100 l/min.
The sensor surface was regenerated between binding reactions by two
washes of 10 mM glycine buffer, pH 9.5, for 15 s at 100 l/min. Identical
injections over blank surfaces were subtracted from the data to deter-
mine specific binding. Binding kinetics were evaluated in a 1:1 binding
model (12).
Human Keratinocyte and Fibroblast Mitogen Assays—The normal
primary human dermal fibroblast line R2F (13) was cultured in Com-
plete fibroblast medium, consisting of Dulbecco’s modified Eagle’s me-
dium/F-12 medium (Invitrogen) supplemented with 15% calf serum
(Hyclone, Inc.) and 10 ng/ml EGF. The normal primary human epider-
mal keratinocyte line N (14) was cultured as described (15) in Complete
keratinocyte medium consisting of Invitrogen keratinocyte serum-free
medium (Invitrogen) supplemented with 30 g/ml bovine pituitary ex-
tract, 0.2 ng/ml EGF, and 0.3 mM CaCl2. Mitogenicity assays were
performed by plating R2F and N cells at low density in reduced serum
and reduced bovine pituitary extract versions of their respective media
formulations and without EGF such that their proliferation in response
to a range of concentrations of added mitogen could be assessed.
3000 R2F cells were plated in replicate 9-cm2 wells in Dulbecco’s
modified Eagle’s medium/F-12 plus 1% calf serum. The next day and
also the fourth day after plating, the wells were refed with this medium
supplemented with a range of EGF and SPGF concentrations or with
complete fibroblast medium. 1000 N cells were plated in replicate 9-cm2
wells in Invitrogen keratinocyte serum-free medium plus 15 g/ml
bovine pituitary extract plus 0.3 mM CaCl2. The next day and also the
fourth day after plating, the wells were refed with this medium supple-
mented with a range of EGF and SPGF concentrations or with complete
keratinocyte medium. The well cultures were trypsinized and counted 6
days after plating. The proliferation rate was measured as population
doublings per day: log2 (number of cells after 6 days/number of cells
plated)/6.
SPGF Biotinylation and Binding to Epithelial Cells Analyzed by
FACS—SPGF was biotinylated using the ECL protein biotinylation
module (Amersham Biosciences) according to the manufacturer’s pro-
tocol. 1  105 MB468 cells (or MB453 cells) were used for each sample.
For direct binding assay (Fig. 2D), 1 aliquot of cells was incubated with
1 g of anti-EGFR blocking antibody (528, Santa Cruz) at 4 °C for 1 h.
Different concentrations of biotinylated SPGF in 50 l of FACS buffer
(1 PBS, 2.5% FCS, 0.02% NaN3) were added to the various cells and
further incubated at 4 °C for 45 min. For competition assays (Fig. 2A),
cells were incubated with 50 l of FACS buffer containing different
amounts of unlabeled SPGF, epiregulin, and EGF at 4 °C for 20 min,
then 25 ng of biotinylated SPGF was added to each tube with further
incubation at 4 °C for 30 min. Cells were washed in FACS buffer, and
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biotinylated SPGF was visualized by streptavidin-phycoerythin (Molec-
ular Probes) using FACS, recording the mean florescence intensity
(MFI). Inhibition was plotted as percentage expressed as (MFI 
MFIneg)/(MFImax  MFIneg).
Cell Lysate Preparation, Immunoprecipitation, and Western Blot-
ting—HeLa cells (80–90% confluent) in 10-cm culture dishes were
stimulated with 50 ng/ml ligands at 37 °C for 10 min. The dish was
washed once with ice-cold PBS. Cells were directly lysed by 1 ml of lysis
buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride, 0.35 trypsin inhibitor units/ml aproti-
nin, 5 g/ml leupeptin, 10 mM NaF, 10 mM -glycerophosphate, and 1
mM Na3VO4) at 4 °C for 30 min. After spinning the samples, 0.5 ml of
lysate was immunoprecipitated by 1 g of anti-EGFR (goat polyclonal,
Santa Cruz Biotechnology) and 10 l of GammaBind plus beads at 4 °C
overnight. Beads were washed 3 times and eluted directly in 2 SDS-
PAGE loading buffer. The total cell lysates and immunoprecipitated
samples were resolved by 7.5% SDS-PAGE followed by Western blotting
to polyvinylidene difluoride membranes. The membrane was blocked in
2.5% BSA, Tris-buffered saline with Tween (TBST) (for EGFR) or 2%
gelatin, TBST (for 4G10) at 37 °C for at least 30 min. Primary antibody
was incubated with membranes overnight at 4 °C according to the
manufacture’s recommendation. Membranes were washed and incu-
bated with 1:10,000 anti-goat IgG (for EGFR) or anti-mouse IgG2b (for
4G10) HRPO conjugates at room temperature for 1 h. After extensive
washing, the membranes were developed using a chemiluminescence
reagent kit (PerkinElmer Life Sciences) on MR film (Eastman Kodak
Co.).
Affinity of SPGF Binding to EGFR—A lactoperoxidase-catalyzed
method was used for labeling SPGF, whereas a chloramine T-catalyzed
method was used for EGF. The specific activity of labeled SPGF was
0.54 pmol/cpm, whereas EGF had 0.34 pmol/cpm. MB468 cells were
plated at 3  104/0.1 ml/96 wells. 125I-Labeled SPGF or EGF was added
at different concentrations in 50 l of binding medium (L15 medium
with 0.1% NaN3) at 4 °C and incubated for 5 h. Supernatants were
harvested, and the cells were quickly washed twice with 60 l of ice-cold
binding medium. The supernatant and the washes were then combined.
50 l of 0.5 N NaOH was added into each well at room temperature for
1 h to lyse the remaining material and further washed once with 60 l
of 0.5 N NaOH. -Counting was used to determine the free ligand in the
culture supernatant as well as the bound ligand in cell lysates. The
affinity, receptor number, and Scatchard plot were calculated.
Antibody Blocking Assay—1 g of anti-EGFR blocking antibody was
added to HeLa cells at 37 °C for 30 min, whereas different amounts of
antibody 2-22 were premixed with 1 ng of SPGF or EGF at room
temperature for 30 min. 1 ng of SPGF or EGF with or without EGFR or
premixed 2-22/SPGF or 2-22/EGF was added to 2  105/ml HeLa cells
in 24-well plates at 37 °C for 10 min. After washing twice with ice-cold
PBS, HeLa cells were lysed in 100 l of lysis buffer and analyzed by
SDS-PAGE and Western blotting as described above.
Molecular Graphics and Modeling—The molecular model of the D4R
(residues 40–90) was derived by homology modeling from the three-
dimensional coordinates of mouse EGF (PDB code 1EGF) using the
package MODELLER (16). Ribbon representations of the structures
were generated using MOLSCRIPT (17) followed by image rendering
with RASTER3D (18). The molecular surface of the D4R model was
generated using GRASP (19). Colored residues in the D4R surface are
the equivalent to those in TGF-, which were found to interact with the
L1 (yellow), L2 (red), or both L1/L2 domains (green) of the erb-B1
receptor in the three-dimensional structure of TGF- in complex with
erb-B1 (Fig. 3). Sequence alignment was made using ClustalW (20) and
structural alignment was guided by the structure superimposition pro-
gram TOP (21) (bioinfo1.mbfys.1u.se/TOP). Mapping of accessibility
D4R onto the structural alignment was carried out using the program
ESPript (22).
Cells and Viruses—Vaccinia virus strain WR was propagated in L929
cells, whereas viral titer assays were performed in Vero cells as previ-
ously described (23, 24). Unpurified vaccinia virus from tissue culture
supernatants was used for all animal infections.
Vaccinia Virus Infections—Male, 6–8-week-old C57BL/6 mice (The
Jackson Laboratory) were injected intraperitoneally with antibody
preparations (200 g of each antibody) diluted in phosphate-buffered
saline except for 2 dosing where 400 g was used. Six hours later,
mice were anesthetized by inhalation of metofane (Pitman-Moore) and
were infected intranasally with 1  104 pfu of vaccinia virus diluted in
50 l of medium.
Lung Histological Virus Titration—At the times indicated, one lung
from each infected animal was harvested, homogenized in minimum
Eagle’s medium supplemented with 10% fetal bovine serum, separated
in aliquots, and frozen at 80 °C. The number of pfu/ml in each lung
was determined by plaque assay using 10% of the homogenate as
previously described (24). The contralateral lung from each VV-infected
mouse was collected, fixed in 10% neutral buffered formaldehyde, and
then paraffin-embedded. Tissue sections (5 m) were stained with
hematoxylin and eosin and analyzed microscopically under 10
magnification.
Analysis of Adaptive T Cell Response—Single cell suspensions were
prepared from spleens, and erythrocytes were removed by lysis using a
0.84% NH4Cl solution. VV-specific CD8
 T cells were detected by meas-
uring IFN- secretion to VV-infected fibroblasts (MC57G) using the
Cytofix/Cytoperm Kit PlusTM (with GolgiPlugTM, Pharmingen). Briefly,
MC57G cells were incubated for 2 h with a 5  106 pfu of WR strain of
VV (multiplicity of infection 1.2). Subsequently, 1–2  106 splenocytes
were incubated in 96-well plates with 2.5  105 VV-infected or unin-
fected MC57G cells in the presence of 10 units/ml human recombinant
IL-2 (Pharmingen) and 0.2 l of GolgiPlugTM for 5 h at 37 °C. After
preincubation with 1 l of Fc BlockTM (2.4G2) in 96-well plates contain-
ing 100 l of FACS buffer (Hanks Balanced Salt Solution, 2% FCS, 0.1%
NaN3), cells were stained (20 min, 4 °C) with combinations of fluoro-
chrome-labeled mAbs specific for CD8 (53-6.7), CD44 (IM7). Subse-
quent fixation and permeabilization of the cells was performed to allow
intracellular access to the anti-IFN mAb (XMG1.2; Pharmingen).
Freshly stained samples were analyzed using a BD Biosciences FACS-
Calibur and CellQuest Software (San Diego, CA). Anti-CD3 stimulation
was used to detect recently activated CD8 T cells. Splenocytes were
incubated with 5 g/ml purified anti-mouse CD3 Ab (145–2C11) under
the same conditions described above.
Effects of SPGF and Anti-SPGF mAbs on Variola Strain Solaimen
Plaque Formation in Vitro—Confluent BSC40 monolayers in two T-162
flasks were infected with variola strain Solaimen at a multiplicity of
infection of 0.1. Cells were incubated at 36 °C, 6% CO2 for 1 h, rocked at
15-min intervals, and overlaid with RPMI supplemented with 2% FBS
(RPMI-2%; 35 ml total volume/flask). The virally infected cells were
incubated at 36 °C, 6% CO2 for 72 h. Harvesting of extracellular envel-
oped virus (EEV) particles was done by pooling the supernatant of the
viral infections into a 250-ml centrifuge bottle. Cell monolayers, con-
taining mostly cell associated virus and IMV, were then rinsed with
media, scraped into media suspension, pooled into two 50-ml conical
tubes, and frozen at 20 °C to be used for future studies.
We estimated that an EEV titer of1.5 104 pfu/ml was obtained in
the viral infection, and we used this figure to dilute the EEV in
RPMI-2% such that we would have 50 pfu/well in the experiment. The
diluted EEV was then split into two 50-ml conical tubes. IMV-neutral-
izing antibody, J2D5 (1:1000), was added to one tube containing diluted
EEV particles to neutralize any IMV particles. Diluted virus with or
without J2D5 was separated into aliquots and deposited into the 2-ml
wells of a 96-well dilution plate. Monoclonal antibodies raised against
SPGF (2-22, 2-13, 13E8, and 11D7) were added to each corresponding
well at a final concentration of 100 g. The virus was incubated with or
without mAbs at 4 °C for 30 min and subsequently plated onto conflu-
ent BSC40 monolayers in 6-well plates. Each mAb was tested in trip-
licate with or without J2D5. Additionally, we tested the effect of pre-
treating the cell monolayer with -EGFR 528 mAb. Three wells of a
6-well plate were pretreated by adding anti-EGFR mAb (1:1000),
whereas the remaining wells were mock-treated with RPMI-2%. The
pretreated plate was incubated at room temperature for 30 min before
adding diluted virus with or without J2D5. All plates were then incu-
bated at 36 °C, 6% CO2 for 1 h and rocked at 15-min intervals. The
inoculum was removed, and 2 ml of RPMI-2% (with or without J2D5)
was added to each well. The plates were incubated at 36 °C, 6% CO2 for
3.5 days at which time they were stained with 2 crystal violet, and
viral plaques were counted. The results in Supplemental Fig. S1 show
that mAbs raised against SPGF marginally inhibit viral plaque forma-
tion by a population of virus that is predominantly EEV. Because the
SPGF is thought to derive from the EEV membrane and EEV particles
are the numerically minor fraction of viruses in the population, this
experiment shows that anti-SPGF mAbs are not neutralizing mAbs.
To determine whether recombinant SPGF can block variola virus
entry into non-transformed human cells, a second type of experiment
was performed. Confluent human foreskin fibroblast monolayers in
6-well plates were pretreated with 1 ml of RPMI-2% with and without
recombinant SPGF at a concentration of 50 nM 60 min before infection.
Cells were then infected at a multiplicity of infection of 5 in 1 ml of total
volume with variola strain Solaimen in RPMI-2% with or without 50 nM
SPGF. Three wells of each plate were pretreated and infected in the
presence of SPGF, and the remaining three wells were mock-treated.
The plates were incubated at 36 °C, 6% CO2 for 1 h and rocked gently
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at 15-min intervals to ensure even infection and coverage of the cell
monolayer. The inoculum was removed, and 2 ml of RPMI-2% with or
without SPGF was added to the appropriate wells. The virally infected
cells were incubated at 36 °C, 6% CO2 and harvested at various times
post-infection. An initial time point was harvested when the viral
inoculum was removed. Harvesting of time points was done by scraping
the cell monolayer from the wells and fully resuspending the viral-
infected cells followed by two freeze-thaw cycles. A 100-l aliquot of
each time point was serially diluted in RPMI-2%. Dilutions 103–108
were plated on BSC40 confluent monolayers in 6-well plates. Plates
were incubated at 36 °C, 6% CO2 for 1 h and rocked gently at 15-min
intervals. The inoculum was removed from each well and 2 ml of
RPMI-2% was added. The plates were incubated at 36 °C, 6% CO2 for
72 h and stained with 2 crystal violet. Plaques were counted, and the
titer of the virus (pfu/ml) was determined. The results in Supplemental
Fig. S2 demonstrate that saturation of erb-B1 sites on human foreskin
fibroblasts fails to block variola entry of IMV and EEV components.
RESULTS
Bioinformatic Analysis and Target Selection—Systematic,
detailed comparison of the complete variola major genes (India
1967 GI:9627521 (185,578 bp) and Bangladesh GI:623595
(186,103 bp)) and those of variola minor (Alastrim GI:5830555
(186,986 bp)), a less pathogenic variant, reveals 97% overall
identity at the nucleotide level (25–27). Likewise, comparison
of variola genes with that of VV (Copenhagen GI: 9790357
(191,736 bp)) shows 95% identity, accounting for smallpox
cross-protection from VV immunization. Because relevant tar-
gets of joint cellular and humoral immunity require both T and
B cell epitopes and necessitate accessibility of antibody to na-
tive viral protein, we searched the variola major genome for
those genes encoding a signal sequence characteristic of many
secreted and integral membrane proteins. Table I lists the 25
candidate genes in the variola major Bangladesh genome
whose products include a signal sequence as defined by SIG-
NALP (28). Using TMHMM (29) and PSORT (30), which iden-
tify transmembrane anchors and other predictors of protein
localization in eukaryotic cells, respectively, these candidates
were divided into two principle groups, type I integral mem-
brane proteins and secreted proteins.
Functional annotation was then accomplished by 1) sequence
similarity comparison through BLAST search (31) against NR
and Swiss protein databases, 2) structural homology analysis
by BLAST search to the PDB data base, and 3) domain struc-
ture analysis using SMART (32) and PFAM (33). Type I inte-
gral membrane proteins include: D4R, a homologue of human
epiregulin (EPI); A46R, C9L, and J7R membrane glycopro-
teins, the latter being hemagglutinin-like; A41L, a homologue
of an integrin-associated protein; B6R, a transmembrane com-
plement control protein with four concatamerized domains,
analogous to the soluble D15L molecule. Predicted secreted
molecules include: D7L, a candidate IL-18-binding protein;
A44L and G3R, orthologues of cowpox-soluble secreted chemo-
kine inhibitors; B8R, structurally related to the extracellular
region of human interferon  receptor; B17R, a structurally
related ligand binding domain of the human IL-1 receptor;
C2L, a homologue of human plasminogen activation inhibitor.
From this analysis and consistent with other earlier pub-
lished data (3, 4, 25), it is clear that the variola immune evasion
strategy is, in significant part, to block inflammation normally
induced by chemokines, cytokines, complement and plasmino-
gen activation. This inflammation blockade permits variola
virus to function as a high fidelity replicon without the need to
exploit mutational mechanisms to escape immune detection.
The variola virus D4R gene product is attractive as an immune
system target within the candidate group in several respects.
First, this gene encompasses the counterpart of the vaccinia
growth factor, an EGF-like ligand that has been involved in the
pathogenesis of vaccinia (6). For this reason we shall refer to
the D4R fragment homolog of VGF as SPGF. Second, among
orthopox viruses, this 140-amino acid gene product is highly
conserved (84–100% amino acid identity) (Fig. 1) yet shares
only 30% amino acid identity with epiregulin, its closest human
homologue encompassing an EGF domain as well. Thus, the
viral product is unlikely to be immunologically cross-reactive
with the mammalian growth factor. Epiregulin shares the
same structural architecture as the orthopox growth factors
(Fig. 1), consisting of a leader sequence, EGF-like ectodomain,
transmembrane segment, and short cytoplasmic tail and binds
to the erb-B family of epidermal growth factor receptors with
differing specificity and biological effect relative to EGF (34,
35). Third, interaction with a variola-derived growth factor
might explain the basis of skin lesions in infected humans since
primary basal skin keratinocytes constitutively express EGF
receptors (36). That VGF was shown to be a pathogenic early
gene product through elegant molecular virology studies (6, 37)
further underscores the potential importance of this target.
D4R Protein Fragment Expression and Cellular Binding—A
high degree of sequence similarity exists within the EGF do-
main of orthopox virus growth factor family members (Fig. 1).
By analogy with native mammalian EGF and VGF, which
exist as membrane-associated precursors post-translationally
cleaved to liberate soluble factors (38), the D4R protein was
expected to be similarly processed. Therefore, we expressed a
D4R protein fragment corresponding to SPGF as inclusions in
E. coli using an N-terminally His-tagged protein incorporating
the EGF domain (amino acid residues 40–90), refolded, and
purified by high performance liquid chromatography as de-
scribed (see “Experimental Procedures”). This recombinant
DNA expression strategy obviated requirements to accommo-
date the N-linked glycan adduct N-terminal to the EGF domain
as well as four conserved putative O-linked glycan sites, two
flanking the N-linked site and two proximal to the transmem-
brane region (Fig. 1). In Fig. 2, panel A, the inset shows a
Coomassie-stained 15% SDS-PAGE gel of purified SPGF mi-
grating as an 8-kDa band as compared with recombinant EGF
at 6 kDa and EPI at 5 kDa. The relative affinity of these three
ligands for human MB468 epithelial cells was tested by flow
cytometry in panel A. Cellular binding of the growth factors
was assayed using biotinylated-SPGF plus streptavidin-phyco-
erythrin with prior incubation of varying amounts of unlabeled
SPGF, EGF, or EPI. Note that the EGF and SPGF binding
inhibition curves are similar, but EPI requires an 10-fold
higher concentration to achieve 50% inhibition. Fig. 2B shows
Scatchard analysis of 125I-labeled SPGF on MB468 cells. Two
receptor classes are defined; they are a high affinity class with
a Kd  0.14 nM and 5.5  10
4 sites per cell and a low affinity
class with a Kd  258 nM and 8.8  10
6 sites per cell. After
binding, SPGF is able to induce proliferation of human kerati-
nocytes (N) and fibroblasts (R2F), supporting long term cell
growth at subnanomolar concentrations, consistent with the
functional relevance of the high affinity sites (Fig. 2C). The Fig.
2C inset represents a 4G10 anti-phosphotyrosine Western blot
of total cell lysates from unstimulated, SPGF-, EGF-, or EPI-
stimulated epithelial cells. Note how the same cellular sub-
strates are phosphorylated for each of the three ligands. SPGF,
like EPI and EGF, also induces phosphorylation of the EGFR.
SPGF Binding to erb-B1—There are four subtypes of EGF
receptors: erb-B1, erb-B2, erb-B3, and erb-B4. The tumorigenic
leporipoxviruses, Shope fibroma virus, and myxoma virus and
the cytolytic vaccinia Orthopoxvirus all display unique patterns
of erb-B receptor kinase interaction relative to each other (10).
Whereas the Shope growth factor is a broad specificity ligand,
VGF primarily binds erb-B1, and the myxoma virus growth
factor binds to erb-B2/erb-B3 heterodimers. To determine
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which receptor binds SPGF, two sets of binding experiments
were performed with biotinylated SPGF using the MB453 (erb-
B1B2B3B4) and MB468 (B1B2B3B4) human epi-
thelial cell lines and flow cytometry. As shown in Fig. 2D, at no
concentration of SPGF is binding detected on MB453 cells. By
contrast, MB468 cells bind SPGF in a dose-dependent manner,
and this binding is readily blocked with the anti-erb-B1-specific
mAb 528. These results show that erb-B1 is necessary for
SPGF binding. To determine whether erb-B1 alone or in con-
junction with erb-B3 is required for SPGF binding, chemical
cross-linking of biotinylated SPGF was performed after binding
to MB468 cells followed by receptor subtype-specific antibody
immunoprecipitation and Western blotting with streptavidin-
HRPO. The Fig. 2D, inset demonstrates that only erb-B1 inter-
acts with SPGF in a detectable manner.
Affinity and Specificity of Anti-SPGF Monoclonal Antibod-
ies—In view of the subnanomolar affinity of SPGF binding to
erb-B1, any attempt at blockade of the viral growth factor-
cellular receptor interaction and downstream signaling re-
quires a high affinity antibody. To this end, we developed mAbs
in Balb/c mice to SPGF first by screening for ELISA reactivity
against the immunizing SPGF, then testing those reactive an-
tibodies for their ability to inhibit biotinylated-SPGF binding to
erb-B1-expressing epithelial cells and subsequently determin-
TABLE I
Analysis of variola major genes containing a leader sequence in the Bangladesh strain
Gene (GenBankTM
accession no.)
Amino
acid Cleavage
a Transmembraneb PDBHITc Domains
d (x) Comments
D4R (438919) 140 20 100–125 1EGF EGF_HUMAN PF0008: EGF (1) Homolog of human epiregulin
(GenBankTM accession no. 7438519).
Epidermal growth factor.
D7L (438922) 126 17 None None None Homolog of IL-18-binding protein
(GenBankTM accession no. 8099344).
D15L (438930) 263 20 None 1G40 VCP_VACCV PF00084: SCR (4) Ortholog of vaccinia complement control
protein (VCP_VACCV). Homolog of
variola B6R.
O2L (438937) 220 18 None 1IAL: A (0.2) None PDB hit points to the arm repeat
(PF00514) of mouse importin 
(GenBankTM accession no. 6754474).
C2L (438940) 373 16 None 1DB2 PAI1_HUMAN PF00079: Serpin (1) Member of the serine protease family.
Homolog of human plasminogen
activator inhibitor (PAI1_HUMAN).
C9L (438947) 348 47 312–334 1DCL: A (0.66) None Variola 36-kDa major membrane
glycoprotein PDB hit points to the IG
domain of GenBankTM accession no.
126559.
A41L (439062) 277 23 125–147,
154–176,
186–208,
215–237,
247–269
None None Homolog of integrin-associated protein
(GenBankTM accession no. 7208759).
A44L (439065) 218 18 None 1CQ3: A
VCCI_COWPOX
PF02250:
ORTHOPOX_35kD (1)
Homolog of cowpox-soluble secreted
chemokine inhibitor VCCI_COWPOX)
and variola G3R.
A46R (439067) 195 22 167–189 None None Membrane glycoprotein.
J7R (439077) 313 17 278–300 1F3R: B PF00047: IG (1) Hemagglutinin antigen, adhesion
molecule.
B4L (439082) 85 25 None None None Unknown. This protein is only present
in variola.
B6R (439084) 317 20 280–302 1G40 VCP_VACCV PF00084: SCR (4) Homolog of D15L and vaccinia
complement control protein
(VCP_VACCV).
B8R (439086) 266 17 None 1FYH: B
INGR_HUMAN
None Homolog of human interferon  receptor
(INGR_HUMAN). May bind IFN.
B17R (439095) 354 23 None 1ITB: B
IL1R_HUMAN
PF00047: IG (2) Homolog of human IL-1 receptor
(IL1R_HUMAN). May bind IL-1.
B22R (439100) 1897 19 1834–1856 None None Unknown. Contains internal repeats.
G2R (439102) 348 23 None 1TNR: R
TNFR1_HUMAN
PF00020: TNFR (3) Homolog of human TNF receptor 1
(TNFR1_HUMAN). May bind TNF.
G3R (439103) 253 18 None 1CQ3: A
VCCI_COWPOX
PF02250:
ORTHOPOX_35kD (1)
Ortholog of cowpox-soluble-secreted
chemokine inhibitor
(VCCI_COWPOX). Homolog of variola
A46L.
E5R (438964) 341 27 None None None Unknown
E10R (438969) 95 22 None None None Unknown
K5L (438977) 79 27 49–71 None None Unknown
H3L (438982) 111 18 None None None Unknown
A14L (439035) 68 22 None None None Unknown
A15L (439036) 90 30 46–68 None None Unknown
A22L (439042) 117 21 None None None Unknown
A31.5L(623596) 146 24 None None None Unknown
a Cleavage sites of N-terminal signal sequences were predicted using SIGNALP (4). Note that orthopox viruses exist in two major particle forms,
the IMV particle and the EEV particle (22).
b Transmembrane regions were detected using the program TMHMM (23).
c Sequences were blasted against the PDB database, and the most significant hit is reported here (e  0.01) along with the name of the sequence
hit in Swiss-prot format (protein_specie). Suboptimal hits (0.01 e 1) are also reported and will be subject to further analysis. The sequence name
is not given for suboptimal hits.
d Domains were detected using PFAM (9). PFAM domain IDs are indicated, as well as the number of times (x) the domain is found in the protein.
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ing the affinity of blocking mAbs by BIAcore. Surprisingly,
antibodies directed against the N-terminal linker proximal to
the EGF domain all augmented SPGF binding to erb-B1-ex-
pressing cells (data not shown). This effect may result from
reduced SPGF tumbling rates in solution, essentially pre-con-
figuring the interaction surface of SPGF for erb-B1 binding. In
contrast, antibodies directed at the EGF domain blocked cellu-
lar binding. Kinetic analysis (Fig. 3, A and B) for two repre-
sentative antibodies of the blocking type, 2-22 and 13E8, shows
a 20-fold difference in the affinity for SPGF, primarily as a
result of the enhanced 2-22 off-rate.
The mAb specificity for other orthopox virus growth factors
was assessed on VGF (Copenhagen) produced and purified in a
manner identical to SPGF. 2-22 fails to bind to VGF (data not
shown), whereas 13E8 shows binding to VGF but with activity
reduced 10-fold relative to SPGF (Fig. 3, A and B). Because the
recombinant SPGF and VGF proteins differ at only 3 of 51
residues within the EGF domain, two residues predicted to lie
within the 1-2 loop and one residue predicted in the 2
strand by structure-based alignment, one or more of these
residues directly or indirectly reduces 13E8 mAb affinity (Fig.
3C). Based on homology modeling using the recent structure of
TGF--erb-B1 and EGF-erb-B1 co-complexes (40, 41) (Fig. 3D),
the non-conservative I18D mutation may readily influence
mAb binding without involving EGFR contacts. Importantly,
2-22 specifically blocks SPGF- but not EGF-induced tyrosine
kinase activity of epithelial cells (Fig. 3E), thus being specific
for the viral protein. Such inhibition requires a 1000-fold molar
FIG. 1. Conservation of epiregulin-like growth factors among orthopox viruses. Examples of orthopox virus growth factor sequences for
variola major, variola minor, vaccinia, cowpox, camelpox, and monkeypox viruses are shown in the single-letter amino acid code. The orthopox virus
strain and gene name, encoded protein length, and identity/similarity to variola Bangladesh are given. The predicted leader sequence, EGF
domain, and transmembrane region are shaded in blue, yellow, and orange, respectively. The six cysteine residues that form three sets of disulfide
bonds characteristic of EGF domains are highlighted in black. The potential N-linked glycosylation site (www.cbs.dtu.dk/services/NetNGlyc) and
O-linked glycosylation sites (53) are denoted by the solid star and circles, respectively. The two solid triangles demarcate the mature human
epiregulin boundaries (39). Alignment was made using ClustalW (20). Residues shaded in gray signify the only variable positions in the analysis
of these sequences. TMM, transmembrane segment.
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excess of antibody over SPGF. Similar results were observed
with 13E8 and 11D7, two other mAbs that cross-block 2-22
(data not shown). Collectively, the data reveal two features of
antibody reactivity against orthopox growth factor proteins. 1)
Cross-reactivity between closely related gene orthologues is not
assured, and 2) high affinity interaction (such as occurs be-
tween erb-B1 and SPGF) requires appropriate mAb affinity,
molarity, and specificity to block a pathogenic factor effects on
host cells.
In Vivo Murine Model Protection Analysis—Given the ability
of 11D7 and 13E8 mAbs to bind VGF, we assessed the protec-
tive effects of their parenteral administration in a VV-induced
pneumonia model in mice (42). To this end, a LD50 (1 10
4 pfu)
of vaccinia virus (WR) was given intranasally 6 h after a single
intraperitoneal injection with 200 g of 11D7, 13E8, or an
irrelevant negative control mAb (1A3). As a positive control, a
known neutralizing mAb (7D11) against the IMV particle pro-
tein L1R was administered (43). Fig. 4A shows the results of
representative experiments when mice were analyzed 7 days
post-infection. Although the neutralizing antigen L1R mAb
reduced the viral titer of pfu in lung by 100-fold, the anti-
SPGF mAbs 11D7 or 13E8 were without effect. These data
suggest that orthopox virus growth factor is not a neutraliza-
tion target, as further confirmed by in vitro analysis (Figs. S1
and S2). Consequently, we performed a second set of experi-
ments using either the L1R-specific mAb alone or in combina-
tion with 13E8. We reasoned that inhibition of viral transloca-
tion into cells by anti-L1R would retard initial IMV replication.
Because IMV entry is facilitated by actin and ezrin protrusions
stimulated by protein phosphorylation (44) and growth factor-
triggered cellular activation enhances viral replication and
subsequent viral particle release from cells, blockade of erb-B1
interaction with VGF/SPGF could further limit viral infectiv-
ity. We, therefore, treated mice with control 1A3 mAb, anti-
SPGF 13E8 alone, anti-L1R alone, or anti-SPGF 13E8 and
anti-L1R mAbs together and examined intranasally infected
mice for lung viral titers on days 4, 6, and 8 post-infection. Fig.
4B shows that the protective effect of anti-L1R alone was
FIG. 2. Interaction of SPGF with human epithelial cells; binding and functional analyses. A, relative ligand affinity for EGF receptors.
Unlabeled ligands at indicated concentrations (abscissa) were incubated with cells followed by the addition of 250 ng of biotinylated SPGF to
compete with “cold” ligands. The bound biotinylated SPGF was visualized by streptavidin-phycoerythrin, and the percentage of maximal binding
(i.e. in the absence of cold competition) was calculated (ordinate) from the mean fluorescence intensity of the FACS analysis. The inset shows a
Coomassie-stained 15% SDS-PAGE of 5 g of SPGF, mammalian epiregulin (34) and human EGF (Sigma). B, Scatchard analysis of SPGF binding
to MB468 cells. 125I-Labeled SPGF was used, and binding affinity and receptor numbers were determined (as described under “Experimental
Procedures”). C, relative mitogenicity of EGF and SPGF for normal human dermal fibroblasts and epidermal keratinocytes. Proliferation was
measured as population doublings per day over a 6-day interval. Replicate cultures were performed that did not vary more than 10%. The inset
shows Western blotting of total HeLa cell lysates (upper panel) and EGFR immunoprecipitation (lower panel) using 4G10 anti-phosphotyrosine-
specific mAb. D, SPGF binding specificity for erb-B1. MB453 and MB468 cell lines were incubated with biotinylated SPGF in the presence or
absence of anti-erb-B1 blocking antibody followed by streptavidin-phycoexythrin, staining and FACS analysis. The MFI number represents mean
fluorescence intensity of fluorochrome staining. Inset, Western blotting of EGFR subtype-specific immunoprecipitates (B1, B2, B3, and B4) after
1) biotinylated SPGF binding to MB453 and MB468 plus chemical cross-linking, developed with streptavidin-HRPO, and 2) parallel probing with
receptor subtype-specific polyclonal antibodies. IP, immunoprecipitates; WB, Western blot.
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FIG. 3. High affinity mAbs block SPGF-triggered cellular activation. A, analysis by surface plasmon resonance of virus growth factor
interaction with 2-22 and 13E8 mAbs. Binding sensorgrams at different orthopox virus growth factor concentrations in analyte are indicated, and
1:1 binding model-predicted (black) and experimental (colored) curves are given for each. Residual values are shown below the sensorgrams. B,
kinetic parameters calculated from BIAcore analysis. C, structure-based sequence alignment of EGF and TGF- with epiregulin (EPIR), SPGF
(D4R), and VGF (C11R). The position of 1-3 strands in EGF and TGF- are shown, and surface accessible residues (scale dark blue, light blue,
and white, corresponding to high, medium, and low accessibility (acc)). Numbers 1 and 2 refer to ligand binding domains L1 and L2 of EGFR in
the TGF-EGFR complex (40). Number 3 denotes a residue interacting with L1 plus L2. Residues highlighted in red denote the three amino acids
that differ between D4R and C11R. D, molecular homology model of SPGF. The top figure is a MOLSCRIPT (17) rendition of SPGF with the side
chains of the three residues in D4R differing from VGF (C11R shown). The bottom figure offers a GRASP (19) rendition of SPGF also including the
predicted residues that contact EGFR L1 domain in red, EGFR L2 domain in yellow, and both L1/L2 contacts in green. E, blocking mAbs specifically
inhibit SPGF binding and activation of human epithelial cells. 2-22 mAb is preincubated with SPGF (left panel) or EGF (right panel) then added
to HeLa cells. Cell lysates were analyzed by Western blotting (WB) with 4G10. The sample () represents no ligand addition, whereas the ()
sample represents the addition in the absence of mAb. Numbers indicate the molar ratio of antibody to ligand. Anti-EGFR denotes cell pre-block
by the erb-B1 specific mAb 528.
Immunoprotection Distinct from Viral Neutralization 25845
manifested as early as day 4 and continued through day 8, at
which time all the control mice had died. Co-administration of
anti-SPGF 13E8 plus anti-L1R had little additional effect
through 6 days of post-infection but contributed to a much
greater viral clearance between days 6 and 8. This enhanced
clearance by the antibody combination was consistently seen in
four experiments, with differences of 10-fold at day 7 and
100–1000-fold at day 8. A control 1A3 mAb plus anti-L1R pair
had no such effect (data not shown). Thus, this non-neutraliz-
ing mAb to VGF/SPGF augments protective immunity late in
infection.
If the mAb pair were protecting exclusively by direct inhibi-
tion of viral replication or viral entry, then the reduced viral
growth should have been evident in the earlier time periods.
Given that VV is controlled by IFN-producing T cells, which
peak between days 6 and 8 post-infection (45), the kinetics of
virus reduction suggest that adaptive immunity is involved. We
therefore examined the T cell response in day 7 VV-infected
mice treated with control 1A3 mAb, anti-SPGF 13E8, anti-L1R,
and the combined anti-SPGF 13E8 plus anti-L1R mAbs. We
examined intracellular IFN levels in freshly isolated spleen T
cells stimulated in vitro for 5 h with VV-infected syngeneic
MC57G target cells as specific stimulators or with anti-CD3
mAb, which will stimulate all recently activated T cells. The
experiments showed increasing IFN responses in the
CD44CD8 T cells in the VV-infected treatment groups com-
pared with naive uninfected mice in the order 1A3 (control),
anti-SPGF 13E8, anti-L1R, and anti-L1R and anti-SPGF 13E8
(Fig. 4C). In this and other experiments, the spleens were
enlarged in the anti-L1R and the anti-L1R plus anti-SPGF
13E8 groups such that, for instance, the total number of VV-
specific IFN-producing cells per spleen in combined anti-L1R
plus anti-SPGF 13E8-treated mice was 11-fold higher than the
1A3-treated mice (3.3  1.4  105 versus 0.3  0.1  105, n 
3 per group).
The enhanced level of activated IFN-producing
CD44CD8 splenic T cells in anti-L1R plus anti-SPGF 13E8
mAb-treated mice suggested a reservoir of cells with the poten-
tial to migrate to the lung to combat pulmonary infection. Note
that CD44, an activation marker up-regulated upon T cell
stimulation, is a recyclable receptor for hyaluronan, involved in
leukocyte homing to sites of inflammation (46). To test this
possibility, lungs were collected from uninfected or from day
7-infected and mAb-treated mice and examined by hematoxylin
and eosin staining in tissue sections. As shown in Fig. 5, com-
pared with uninfected mice, where the alveolar spaces are
readily evident and bronchiolar epithelium intact, the infected
control mAb-treated lungs are characterized by necrotic bron-
chiolar epithelia and severe alveolar edema, reflected by the
weight of the VV-infected lung, about twice that of uninfected
lung (0.35 0.04 versus 0.21  0.01 g, n  3). The alveolar
spaces are obliterated, in fact filled with eosinophilic material
and accompanied by few, if any, parenchymal cellular infil-
trates. The degree of cellular infiltration increases somewhat in
mAb 13E8-treated mice, more so in anti-L1R mAb-treated mice
and most dramatically in the combined mAb-treated mice. In
the double mAb-treated group, the alveolar spaces are open,
and bronchiolar epithelia appear normal. This cellular infil-
FIG. 4. Anti-SPGF/VGF mAbs modify murine vaccinia infection in vivo. A, viral titers in lungs of individual male mice after single mAb
treatment. Values are those of individual animals. All animals were treated with 200 g of each mAb administered intraperitoneally 6 h before
intranasal infection with 1  104 pfu of vaccinia virus WR. 1A3 is an irrelevant, control mAb. Lungs were harvested on day 7, post-infection. Only
anti-L1R treatment (denoted L1R) reduced viral titers significantly (p  0.0001 using one-way analysis of variant). B, kinetic analysis of plaques
in VV-infected animals at days 4, 6, and 8. Treatments with 1A3 (control (Ctl.)), 13E8, anti-L1R, or anti-L1R plus 13E8 are shown. Each treatment
group consisted of three animals, with the mean and S.D. values noted. At day 8, all three control (1A3) mice had died, and 2⁄3 if the 13E8-treated
animals had died. C, augmentation of adaptive T cell immunity with mAb therapy. Multiparameter flow cytometry analysis of intracellular IFN
and CD44 expression in splenic CD8 T cells from naive mice or infected untreated mice (control) or infected and treated groups are shown. In vitro
stimulation of in vivo activated T cells is mediated by VV-infected MC57G antigen-presenting cells or anti-CD3 mAb. As a control, results using
uninfected MC57G cells are shown. Kruskal-Wallis statistical analysis of control versus treated animals for antigen-specific and anti-CD3
stimulated T cells showed p  0.038 and 0.042, respectively.
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trate is attributable to CD8 T cells in large part. Leukocytes
isolated from the pooled lungs of three mAb anti-L1R-treated
mice were 25% CD8 and 5% CD4, whereas those isolated from
anti-L1R plus anti-SPGF 13E8-treated mice were 34% CD8
and 8% CD4 T cells. Thus, the non-neutralizing anti-SPGF
13E8 mAb enhances clearance of VV in association with aug-
mented T cell responses in the spleen and lung.
DISCUSSION
In the present study, we used genome-wide bioinformatics to
identify candidate variola major gene products as potential
targets for immune protection. Of these products, D4R was
investigated in detail given that EGF-like growth factors are
carried by other poxviruses to facilitate viral pathogenesis (Fig.
2 and Refs. 6, 10, and 47). A subnanomolar affinity of interac-
tion between the recombinant SPGF fragment and erb-B1 was
noted in the absence of detectable binding to the other mem-
bers of the erb-B family. Using ELISA screening methods in
conjunction with BIAcore binding studies, we identified several
mAbs with specificity for SPGF with or without VGF cross-
reactivity. These mAbs blocked SPGF-induced tyrosine phos-
phorylation of erb-B1 and other mammalian cellular substrates
without affecting EGF-mediated signaling through the same
erb-B1 pathway, consistent with the selective monoclonal an-
tibody specificity for the viral growth factor. Our in vitro plaque
assay data in the presence of SPGF or its blocking antibodies
(Figs. S1 and S2) exclude the possibility that smallpox virus
utilizes D4R attachment to EGFR as a primary means to enter
mammalian cells and are consistent with the VGF deletion
mutant result in the vaccinia system (6). In conjunction with an
anti-L1R mAb directed at the IMV (43), anti-SPGF/VGF mAbs
afforded immunoprotection in a vaccinia pneumonia model.
Importantly, disruption of pathogenic factor-host cell interac-
tion by passive mAb administration is associated with an en-
hanced T cell immunity. Aside from revealing an unexpected
basis for protection and identifying a key orthopox viral target,
our findings suggest a strategy for pathogenic factor blockade
that may have general utility.
The systemic inflammatory component of innate immunity,
the so-called acute phase response, is rapidly induced when
organism integrity is breached (48). Sentinel cells including
epithelial cells produce IL-1 and/or IL-6 during this process
(49). Blockade of erb-B1 stimulation by the anti-SPGF 13E8
mAb may help avoid subsequent cytokine dysregulation (50,
51). Note that EGF and TGF-, two erb-B ligands, can induce
effusions in vivo (52). Orthopox virus growth factors may con-
tribute to an analogous pathology so that 13E8 mAb may be
ameliorating in this regard as well.
The present study identifies anti-viral therapeutic mAbs dis-
tinct from those mediating viral neutralization. Antibodies in
this class afford protection not by blocking viral attachment,
fusion, and/or entry per se (Figs. S1 and S2) but by inhibiting
the action of virus-derived pathogenic factors, i.e. inhibiting the
viral interference. By extension, inhibition of signaling path-
ways directed by those factors may also be advantageous to the
host. In the case of orthopox viruses, multiple viral proteins
that block adaptive and innate immunity are antibody-acces-
sible targets (Table I). Immune modulating antibodies against
one or more of these products may shift the balance from viral
replication and viral-induced pathology in favor of productive
host adaptive immunity. We suspect that targeting of soluble
viral decoy receptors and viral factors interfering with host
chemokines, cytokines, complement, and plasminogen activa-
tion will offer future anti-viral therapeutic strategies.
Anti-orthopox virus growth factor antibody specificities are
not detectable in pooled hyperimmune globulin (vaccinia im-
mune globulin) after human vaccinia immunization (data not
shown). Likely, the rapid internalization of SPGF/VGF through
erb-B1 precludes natural development of antibodies against
this viral product. Hence, more protective targets may exist
than suggested by host immune responses naturally elicited
during the course of infection. The combination of a neutraliz-
ing mAb plus such a protective mAb may be particularly ad-
vantageous and may represent a treatment for complications of
vaccinia immunization or an alternative form of human post-
exposure therapy in the event of variola bioattack.
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FIG. 5. Qualitative and quantitative alterations in pulmonary infiltrates by protective mAbs. Representative hematoxylin and eosin
sections (10 magnification) are shown for lungs from uninfected and infected mice. Pink staining material filling the alveolar spaces in the
infected lung represents edema associated with a proteinaceous exudate. The arrow in the anti-L1R plus anti-SPGF 13E8 double mAb treatment
group refers to the upper of two bronchioles where the epithelial layer is preserved. Results are representative of a minimum of 10 microscopic
fields, examined per slide.
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